Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 484.10, up by 4.00 points or 0.83% from its previous closing of Rs. 480.10 on the BSE.

The scrip opened at Rs. 489.70 and has touched a high and low of Rs. 489.70 and Rs. 483.30 respectively. So far 23,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 656.75 on 19-May-2017 and a 52 week low of Rs. 433.15 on 14-Aug-2017.

Last one week high and low of the scrip stood at Rs. 489.70 and Rs. 459.45 respectively. The current market cap of the company is Rs. 1,15,944.00 crore.

The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.55% and 13.07% respectively.

Sun Pharmaceutical Industries through one of its wholly owned subsidiaries has launched in US, the Authorized Generic (AG) version for Daiichi Sankyo Inc.’s Welchol (colesevelam hydrochloride) 625mg tablets. Welchol Tablets recorded US sales of approximately $520 million for the 12 months ending March 2018, as per IQVIA.

The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.